325 related articles for article (PubMed ID: 30234231)
21. Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
Isaka Y; Hamano T; Fujii H; Tsujimoto Y; Koiwa F; Sakaguchi Y; Tanaka R; Tomiyama N; Tatsugami F; Teramukai S
J Am Soc Nephrol; 2021 Mar; 32(3):723-735. PubMed ID: 33547218
[TBL] [Abstract][Full Text] [Related]
22. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
[TBL] [Abstract][Full Text] [Related]
23. Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients.
Molony DA; Parameswaran V; Ficociello LH; Mullon C; Kossmann RJ
Kidney360; 2020 Apr; 1(4):263-272. PubMed ID: 35372921
[TBL] [Abstract][Full Text] [Related]
24. Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.
Galassi A; Cupisti A; Santoro A; Cozzolino M
J Nephrol; 2015 Aug; 28(4):415-29. PubMed ID: 25245472
[TBL] [Abstract][Full Text] [Related]
25. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
26. Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis.
Kalantar-Zadeh K; Ficociello LH; Zhou M; Anger MS
BMC Nephrol; 2024 Jun; 25(1):197. PubMed ID: 38886636
[TBL] [Abstract][Full Text] [Related]
27. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
.
Coyne DW; Ficociello LH; Parameswaran V; Anderson L; Vemula S; Ofsthun NJ; Mullon C; Maddux FW; Kossmann RJ; Sprague SM
Clin Nephrol; 2017 Aug; 88(8):59-67. PubMed ID: 28587714
[TBL] [Abstract][Full Text] [Related]
28. Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
Schmid H; Lederer SR
Expert Opin Pharmacother; 2015; 16(14):2179-91. PubMed ID: 26293683
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.
Koiwa F; Yokoyama K; Fukagawa M; Terao A; Akizawa T
Nephrology (Carlton); 2017 Apr; 22(4):293-300. PubMed ID: 27496336
[TBL] [Abstract][Full Text] [Related]
30. [Pharmacological profile and clinical findings of a new phosphate binder, ferric citrate hydrate (Riona® Tablets)].
Miyazaki A; Matsuo A; Iida A; Nishino N; Maeda K; Matsumoto Y; Orui S
Nihon Yakurigaku Zasshi; 2014 Dec; 144(6):294-304. PubMed ID: 25492366
[No Abstract] [Full Text] [Related]
31. A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis.
Perez L; You Z; Teitelbaum I; Andrews ES; Reddin R; Ramirez-Renteria L; Wilson G; Kendrick J
BMC Nephrol; 2022 Jul; 23(1):245. PubMed ID: 35810296
[TBL] [Abstract][Full Text] [Related]
32. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
33. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
Koiwa F; Terao A
Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
[TBL] [Abstract][Full Text] [Related]
34. [Iron-based Phosphate Binders for ESRD Patients].
Cozzolino M; Mangano M; Magagnoli L; Di Lullo L; Galassi A; Brancaccio D; Bellasi A
G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545638
[TBL] [Abstract][Full Text] [Related]
35. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
Floege J; Covic AC; Ketteler M; Rastogi A; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
Kidney Int; 2014 Sep; 86(3):638-47. PubMed ID: 24646861
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of sucroferric oxyhydroxide in patients on on-line hemodiafiltration in real-world clinical practice: A retrospective study.
Ferreira A; Pinto B; Navarro D; Aniceto J; Neves PL; Ponce P
J Bras Nefrol; 2019; 41(2):224-230. PubMed ID: 30742699
[TBL] [Abstract][Full Text] [Related]
37. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
Scialla JJ; Kendrick J; Uribarri J; Kovesdy CP; Gutiérrez OM; Jimenez EY; Kramer HJ
Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
[TBL] [Abstract][Full Text] [Related]
38. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
39. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants.
Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM
J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270
[TBL] [Abstract][Full Text] [Related]
40. [Short-term effects with sucroferric oxyhydroxide in hemodialysis patients: Experience in NephroCare France].
Chazot C; Fadel B; Kareche M; Puyoo O; Jean G
Nephrol Ther; 2019 Mar; 15(1):29-34. PubMed ID: 30639044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
